CASI Pharmaceuticals, Inc. (CASI) Scheduled to Post Quarterly Earnings on Monday
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will announce its earnings results on Monday, November 13th.
CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). On average, analysts expect CASI Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
CASI Pharmaceuticals, Inc. (NASDAQ CASI) opened at $2.37 on Monday. CASI Pharmaceuticals, Inc. has a twelve month low of $0.91 and a twelve month high of $4.84.
A number of equities analysts recently issued reports on CASI shares. ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 15th. Maxim Group reiterated a “buy” rating and issued a $4.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th.
In related news, Director Wei-Wu He purchased 207,502 shares of the stock in a transaction that occurred on Tuesday, September 19th. The stock was acquired at an average cost of $1.75 per share, with a total value of $363,128.50. Following the transaction, the director now owns 513,525 shares of the company’s stock, valued at approximately $898,668.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders purchased a total of 996,329 shares of company stock valued at $1,647,138 over the last three months. 13.01% of the stock is currently owned by insiders.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.